Spirit Scientific (7790), a Taiwanese regenerative medicine startup, has launched its autologous platelet-derived cellular signal factors lyophilization services. This innovation follows the recent legislative approval of the Regenerative Medicine Law and Regulations in Taiwan, aligning with the “Healthy Taiwan” policy and boosting the competitiveness of the biotech and medical industry.
Cellular signal factors, nanoscale vesicles secreted by cells, act as intercellular messengers containing proteins, mRNA, and other biomolecules. They play crucial roles in tissue repair, immune regulation, and more, offering significant potential in diagnostics and therapeutics. Leveraging nearly a decade of expertise in high-concentration platelet (PLT) lyophilized preparations, Spirit Scientific is now applying its knowledge to cellular signal factors research.
The company’s new service precisely quantifies and qualifies cellular signal factors in each vial, creating a stable lyophilized form. This allows for customized dosage based on individual patient conditions, maximizing effectiveness. The process adheres to stringent GTP standards and the latest international MISEV2023 guidelines, ensuring the quantity, size, characteristics, and purity of the these key signaling factors derived from platelets are strictly controlled. Products undergo gamma-ray sterilization and nine safety tests for guaranteed safety.
Spirit Scientific’s “Biofoundry” concept, utilizing its BMLT®, aims to develop optimal lyophilization processes for various biomaterials, extending their shelf life and increasing application flexibility. The company expects this new service to further contribute to human health by bridging research with clinical applications in regenerative medicine.
Source: 【工商時報】https://www.ctee.com.tw/news/20250224701495-431207
